Tong X, Sei W, Gu M
Xie He Hospital of Tongji Medical University, Wuhan.
Zhonghua Fu Chan Ke Za Zhi. 1997 Dec;32(12):712-4.
The efficacy and toxicity of adenovirus-mediated transduction of herpes simplex virus thymidine kinase gene started by Rous sarcoma virus (ADV/RSV-tk) followed by administration of ganciclovir (GCV) were studied in vivo.
An animal model of human epithelial ovarian cancer was established in nude mice using the serous ovarian adenocarcinoma cell lines Ov-ca-2774, then mice were treated by ADV/RSV-Tk and GCV, or GCV and HSV-tk respectively. The average survival time of mice and toxicity were assessed.
The mice treated with GCV or HSV tk alone died from 14.4 +/- 1.7 to 19.3 +/- 3.5 days after treatment. The survival time had no difference with control group. The mice treated with ADV/RSV-tk followed by GCV lived at least two times longer than controls and the difference in both groups was significant. The earlier the treatment began, the longer the average survival time was. Treatment efficacy was dependent on dose of ADV/RSV-tk and tumor burden of mice.
ADV/RSV-tk gene therapy is a safe and efficient approach to ovarian cancer treatment in the experiment.
研究腺病毒介导的单纯疱疹病毒胸苷激酶基因经劳斯肉瘤病毒启动（ADV/RSV-tk）后给予更昔洛韦（GCV）在体内的疗效和毒性。
使用浆液性卵巢腺癌细胞系Ov-ca-2774在裸鼠中建立人上皮性卵巢癌动物模型，然后分别用ADV/RSV-Tk和GCV或GCV和HSV-tk对小鼠进行治疗。评估小鼠的平均生存时间和毒性。
单独用GCV或HSV tk治疗的小鼠在治疗后14.4±1.7至19.3±3.5天死亡。生存时间与对照组无差异。先给予ADV/RSV-tk再给予GCV治疗的小鼠存活时间比对照组至少长两倍，两组差异显著。治疗开始越早，平均生存时间越长。治疗效果取决于ADV/RSV-tk的剂量和小鼠的肿瘤负荷。
在实验中，ADV/RSV-tk基因治疗是一种安全有效的卵巢癌治疗方法。
